Kythera raises $125M in follow-on

Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) raised $125 million through the sale of 2.6 million shares at $48 in a follow-on underwritten by Goldman Sachs; BofA Merrill Lynch; Leerink; and Cowen. Kythera proposed the offering on Monday after market close, when its shares were valued at $51.17.

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted 17-0 on Monday to back approval of ATX-101 deoxycholic acid to reduce submental (under chin) fat. The injectable synthetic sodium deoxycholate has a May 13 PDUFA date (see BioCentury Extra, March 9). ...